Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC ...
Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC. The phase 3 LAURA trial showed that treatment ...
Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome Technology is seen as transformative in increasing the effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results